|
Facebook
Twitter
Linkedin
|
 |
 |
 |
 |
Positron Corporation Positron Announces Completion of Cardio-Assist(TM);Set for Early 2011 Deployment
Positron Announces Completion of Cardio-Assist(TM);Set for Early 2011 Deployment
Monday, 08 November 2010 04:05 | 
| Company News - Positron Corporation |
Positron Corporation announced it has completed development of its proprietary automated compounding and unit dose dispensing device, Cardio-Assist(TM)
Positron Corporation, a leading molecular imaging company specializing in the field of nuclear cardiology , announced it has completed development of its proprietary automated compounding and unit dose dispensing device, Cardio-Assist(TM), which will be installed in coming weeks at a functioning clinical site for final acceptance. The Company expects to commence commercial deployment during the first quarter of 2011.
"Today marks an important milestone for Positron - since acquiring Dose Shield in 2008, we've worked diligently to get this product to market with precision, speed and efficiency. We have successfully delivered on our pharmaceutical projects that have exceeded both internal and external development requirements as well as timing targets which is a true testament to the entire team. With our current product mix, the Attrius (R) PET scanner, Cardio-Assist(TM) and our state-of-the-art radiopharmaceutical manufacturing facility, we have positioned Positron to be a unique and true leader in the nuclear cardiology marketplace," said Patrick G. Rooney, chief executive officer of Positron.
Commensurate with the Company's acquisition of Dose Shield in June of 2008, Positron and Dose Shield set a 36-month timeline to reach its goals of developing an automated virtual nuclear pharmacy and a fully functional radiopharmaceutical manufacturing facility. These developmental milestones mark the completion of the Company's objectives; approximately 7 months ahead of schedule. Mr. Zehner who joined the Company in the acquisition of Dose Shield has successfully executed the Company's objectives per terms of his employment agreement; as such he has resigned as Positron 's COO and will continue to serve the Company as a pharmaceutical consultant.
Source: Positron Corporation
Click on the link to see more PET Scanners
